Fintel on MSN
Piper Sandler initiates coverage of Perspective Therapeutics (CATX) with overweight recommendation
Fintel reports that on February 19, 2026, Piper Sandler initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a ...
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of ...
Perspective Therapeutics (CATX) has been on a downward spiral lately with significant selling pressure. After declining 16.6% over the past four weeks, the stock looks well positioned for a trend ...
Shares of Perspective Therapeutics (CATX) have gained 19.3% over the past four weeks to close the last trading session at $12.34, but there could still be a solid upside left in the stock if ...
On Thursday, Cantor Fitzgerald initiated coverage on Perspective Therapeutics Inc (NYSE: CATX) stock, assigning an Overweight rating. The firm sees CATX as a compelling investment opportunity, ...
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Sector Outperform recommendation. As of March 4, 2025, the average one-year price ...
Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a targeted radiopharmaceutical for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results